{
  "docId": "019de073-d0ca-7288-9ab4-c51009336f37",
  "docSlug": "2ef2fad38453444b0a07cd5e908bf527",
  "documentTitle": "PaxMedica | Investor Presentation Deck | 24 slides",
  "authorId": "paxmedica",
  "authorName": "PaxMedica",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 8,
  "pageCount": 24,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "other",
  "function": "other",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Focuses on regulatory strategy and potential financial upside from FDA Priority Review Vouchers.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de073-d0ca-7288-9ab4-c51009336f37/8",
  "deckHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37",
  "deckJsonHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37.json",
  "deckAnchorHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.43
      },
      "kind": "list",
      "text": "Currently only approved in Africa, where PaxMedica has the exclusive license to suramin-treated patient data from key endemic hospitals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21d638ba-29b0-43c4-aed9-134ec330393d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "NDA Sponsors under this program may qualify for FDA benefits, including a Priority Review Voucher. Market exclusivities up to seven (7) years are also expected to be granted",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37db8c4c-908b-4f6f-b999-37faf70d7f09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.53
      },
      "kind": "list",
      "text": "PAX-101 received FDA Orphan Drug Designation for this neglected tropical disease in Nov. 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a612f785-2518-47ec-8622-1c0705e62ccc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "list",
      "text": "PaxMedica intends to file an NDA for the use of PAX-101 in HAT infections in late 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b243472f-2a98-41fb-bc1f-35be95f4885b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "list",
      "text": "IV suramin is the standard of care in the treatment of potentially lethal infections caused by Stage 1 T. Brucei Rhodesiense Human African Trypanosomiasis (HAT), aka African Sleeping Sickness, for over 100 years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa05c9f6-5c30-466d-b677-5a353c28f1d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "Priority Review Vouchers (PRV) have been transacted at values > $100 million. PRV Vouchers can potentially be sold to a third party upon receipt following NDA approval",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffc632c8-927c-4425-9dc2-a1e42a6268ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Potential Value and Liquidity Via Early NDA Submission",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a38746db-9063-4dc4-98da-0f2dc8e1e929",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "title",
      "text": "Priority Review Voucher Program for Neglected Tropical Diseases - HAT",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "865487b8-2c12-499f-9e35-e82b3c80d066",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}